JP2013505734A5 - - Google Patents

Info

Publication number

JP2013505734A5

JP2013505734A5 JP2012531494A JP2012531494A JP2013505734A5 JP 2013505734 A5 JP2013505734 A5 JP 2013505734A5 JP 2012531494 A JP2012531494 A JP 2012531494A JP 2012531494 A JP2012531494 A JP 2012531494A JP 2013505734 A5 JP2013505734 A5 JP 2013505734A5

Authority

JP

Japan

Prior art keywords

tcr

chain

seq

cell

ebv

Prior art date

2010-09-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 40
• 108091008874 T cell receptors Proteins 0.000 claims description 39
• 239000002773 nucleotide Substances 0.000 claims description 19
• 125000003729 nucleotide group Chemical group 0.000 claims description 19
• 210000004027 cell Anatomy 0.000 claims description 17
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
• 235000001014 amino acid Nutrition 0.000 claims description 5
• 150000001413 amino acids Chemical class 0.000 claims description 5
• 201000010099 disease Diseases 0.000 claims description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 4
• 108090000623 proteins and genes Proteins 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 101710169959 Membrane protein 2 Proteins 0.000 claims description 2
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
• 230000015572 biosynthetic process Effects 0.000 claims description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
• 238000000338 in vitro Methods 0.000 claims description 2
• 230000035772 mutation Effects 0.000 claims description 2
• 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
• 210000000130 stem cell Anatomy 0.000 claims description 2
• 230000002463 transducing effect Effects 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 5
• 208000032420 Latent Infection Diseases 0.000 claims 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 11
• 238000000034 method Methods 0.000 description 4
• 230000007423 decrease Effects 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1